Noom Offers Oral Medications For Weight Loss Starting at $29
A $29 entry price helps provide accessibility for people pursuing weight loss goalsService includes all features of Noom Med ...
Noom just expanded its drug offerings with a weight-loss pill
The digital health company Noom announced Thursday that it is expanding its weight-loss drug offerings to include pills, ...
Oral Anti-Diabetic Drug Market Expands As Healthcare Providers Focus On Early Intervention And Prevention Market Trends & Business Updates
The global Oral Anti-Diabetic Drug market is poised for substantial growth, driven by increasing diabetes cases, advancements ...
Cipla gets CDSCO nod to market insulin inhalation powder for diabetes management
Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin ...
Boulder drug discovery co. attracts Merck as an investor
A Boulder-based company that is developing a orally-delivered drug for obesity and metabolic disorders just reached $25M in ...
Taiwan News1d
Saudi Arabia Diabetes Drug Market Adoption Trends in Technology and Innovation
Taiwan says China sending largest naval fleet in years to region The Saudi Arabia diabetes drug market is a vital segment of the pharmaceutical industry, catering to the needs of a significant portion ...
The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials
Eli Lilly ( NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight ...
BioAge scraps mid-stage trial of experimental obesity drug
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of ...
4 oral GLP-1R obesity drugs in race for approval, Novo Nordisk leads: Report
Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...
GEN8d
Lonza Expands Smart Capsule Offering for Companies Developing Oral Delivery Solutions for Biologic Drugs
Delivering biologics via oral administration represents a growing market that is expected to exhibit 35% CAGR from 2023–2028.
Torrent Pharma strengthens anti-diabetes portfolio with acquisition of three brands from Boehringer
"The acquisition is expected to be completed in March 2025. Torrent has been marketing these brands since 2022 as part of an ...
BioAge scraps mid-stage trial of experimental obesity drug, shares fall
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes were observed in some patients, sending its shares down ...